Healthcare-focused social commerce company Alphaeon said Monday it inked an agreement to acquire all of the assets of laser cataract treatment company Lensar for $59 million.
Lensar develops and manufactures Femtosecond Lasers Systems designed specifically for refractive cataract surgery, the company said.
“Lensar has advanced the self-pay category of precision refractive surgery both for ophthalmologists as well as their patients. The addition of Lensar to our lifestyle product portfolio will provide ophthalmologists with another alternative to expand their offering to patients. We are very pleased at the opportunity to welcome Lensar employees to our expanding global team,” Alphaeon CEO Robert Grant said in a press release.
The $59 million transaction will be paid in cash, stock and assumed debt and is expected to close on or before Dec. 31 this year, Orlando, Fl.-based Lensar said.
“The opportunity to partner with Alphaeon furthers Lensar’s commitment to provide ophthalmologists everywhere with the latest developments in premium vision surgery. We’re excited with the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike,” Lensar CEO Nick Curtis said in prepared remarks.